Huma is an Associate Director with Cofactor Group. Her 15+ years of healthcare experience includes research in nuclear medicine and strategic consulting for emerging and top-tier pharmaceutical manufacturers.
While at Cofactor Group, her key areas of focus have been leading engagements in medical launch preparedness, real world evidence strategy and planning, medical strategy, and operational planning / execution. She has experience in various therapeutic categories including Cardiovascular, Metabolic Disorders and Oncology. Prior to joining Cofactor Group, she was a NIH Postdoctoral Research Fellow in Nuclear Medicine at Harvard Medical School. She is the coauthor of multiple peer-reviewed publications on chemistry and nuclear medicine. Her research experience includes collaborating with chemistry and pharmaceutical companies on development of new nuclear medicine products.
She holds a Ph. D. in Chemistry from the University of Missouri-Columbia and BS degree in Chemistry from St. Louis University.
Cofactor partnered with a biotechnology organization to inform critical investment decisions about a potential treatment for SARS-CoV-2 infection.
Co-commercialization or co-promotion agreements have become the new norm in the life sciences industry, and all have one thing in common - they are challenging. Cofactor provides specific alliance expertise, capabilities, and tools that can help your alliance work more effectively.